3 ASX Growth Companies With High Insider Ownership Growing Earnings Up To 44%
As Australia's reporting season kicks into gear, the ASX 200 is facing a cautious start, with futures indicating a slight dip amidst global uncertainties and geopolitical tensions. In such an environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, potentially driving robust earnings performance even in challenging market conditions.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 10.2% | 88.3% |
| Titomic (ASX:TTT) | 14.7% | 72.7% |
| Starpharma Holdings (ASX:SPL) | 21.8% | 91.8% |
| SKS Technologies Group (ASX:SKS) | 28.2% | 42% |
| Predictive Discovery (ASX:PDI) | 10.4% | 63.6% |
| Pinnacle Investment Management Group (ASX:PNI) | 25% | 20.9% |
| Forrestania Resources (ASX:FRS) | 31.9% | 126.7% |
| Austral Resources Australia (ASX:AR1) | 22.9% | 36.8% |
| Auric Mining (ASX:AWJ) | 19.6% | 29.2% |
| Adveritas (ASX:AV1) | 17.6% | 107.8% |
Below we spotlight a couple of our favorites from our exclusive screener.
Guzman y Gomez (ASX:GYG)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guzman y Gomez Limited operates quick service restaurants in Australia, Singapore, Japan, and the United States with a market cap of A$2.52 billion.
Operations: The company generates revenue primarily from its quick service restaurant operations, amounting to A$516.47 million.
Insider Ownership: 16.7%
Earnings Growth Forecast: 34.9% p.a.
Guzman y Gomez is poised for significant growth, with earnings forecast to increase 34.9% annually, outpacing the Australian market's 11.2%. Despite slower revenue growth at 13.8%, profitability has been achieved this year. The company recently completed a A$100 million share buyback, enhancing shareholder value by repurchasing over 5% of its shares. However, it faced setbacks by being dropped from the S&P/ASX 200 Index and Consumer Discretionary Sector Index in June 2026.
- Navigate through the intricacies of Guzman y Gomez with our comprehensive analyst estimates report here.
- The valuation report we've compiled suggests that Guzman y Gomez's current price could be inflated.
MA Financial Group (ASX:MAF)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MA Financial Group Limited operates in Australia, offering a range of financial services through its subsidiaries, with a market cap of approximately A$995.73 million.
Operations: The company's revenue segments include Asset Management generating A$217.55 million, Lending & Technology with A$96.79 million, and Corporate Advisory and Equities (CA&E) contributing A$68.70 million.
Insider Ownership: 33.9%
Earnings Growth Forecast: 25.7% p.a.
MA Financial Group faces challenges with an expected annual revenue decline of 26.1% over the next three years, but its earnings are projected to grow significantly at 25.7% annually, surpassing the market average. Despite recent insider selling and a profit margin drop from 3.8% to 0.7%, analysts anticipate a stock price increase of 76.8%. The dividend yield of 3.57% is not well covered by earnings, highlighting financial sustainability concerns amidst high insider ownership in Australia’s growth sector.
- Click to explore a detailed breakdown of our findings in MA Financial Group's earnings growth report.
- Our valuation report unveils the possibility MA Financial Group's shares may be trading at a premium.
Telix Pharmaceuticals (ASX:TLX)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$4.85 billion.
Operations: The company generates revenue from segments including Therapeutics ($9.27 million), Precision Medicine ($621.93 million), and Manufacturing Solutions ($245.11 million).
Insider Ownership: 14.8%
Earnings Growth Forecast: 44.5% p.a.
Telix Pharmaceuticals demonstrates promising growth potential with revenue expected to rise 13.9% annually, outpacing the broader Australian market. Despite trading significantly below its estimated fair value, Telix is forecasted to achieve profitability within three years. Recent strategic alliances, such as with Regeneron Pharmaceuticals, enhance its position in precision medicine. Insider transactions show more buying than selling recently, indicating confidence in ongoing developments like their prostate cancer therapies and anticipated revenue exceeding US$1 billion for 2026.
- Click here to discover the nuances of Telix Pharmaceuticals with our detailed analytical future growth report.
- Our valuation report unveils the possibility Telix Pharmaceuticals' shares may be trading at a discount.
Next Steps
- Delve into our full catalog of 103 Fast Growing ASX Companies With High Insider Ownership here.
- Want To Explore Some Alternatives? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com